Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | VIR-5818 |
| Trade Name | |
| Synonyms | AMX 818|AMX818|VIR5818|VIR 5818|AMX-818 |
| Drug Descriptions |
VIR-5818 is a prodrug T-cell engager that targets CD3 and ERBB2 (HER2) which is activated in the tumor microenvironment, potentially resulting in activation of an immune response against ERBB2 (HER2)-expressing tumors and inhibition of tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P193). |
| DrugClasses | CD3 Antibody 119 HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | NA |
| NCIT ID | C187696 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Pembrolizumab + VIR-5818 | Pembrolizumab VIR-5818 | 0 | 1 |
| VIR-5818 | VIR-5818 | 0 | 1 |